^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + zilovertamab (UC-961) (ROR1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1/2 Study of zilovertamab and ibrutinib: durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease
Published date:
10/06/2023
Excerpt:
The PFS and OS for the subgroup with TP53 mut/del(17p) are particularly encouraging in reference to other trials of BTK inhibitors, maintaining 100% PFS and OS at ∼42 mos.
DOI:
https://doi.org/10.1080/10428194.2023.2250219
Source:
Title:
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
Published date:
06/09/2023
Excerpt:
Efficacy in MCL...7 pts with TP53 mutation had ORR of 85.7% with mPFS NR and 14 pts with Ki-67 ≥30% had ORR of 85.7% with mPFS 33.2 mos. Overall, median OS was NR (95% CI: 22.46, NE)...Zilo+Ibr is well-tolerated with a safety profile that is comparable to Ibr alone. AF (all grades) occurred in 9.4% of all pts treated which appears lower than rate in Ibr alone studies. The combination is very promising in pts with RR MCL (ORR 89.3%, CR 42.9%, mPFS NR). For CLL pts with TP53 mut/del(17p), Zilo+Ibr is also very active, maintaining 100% PFS and OS at ∼42 mos.
DOI:
10.1002/hon.3164_440
Source:
Title:
232 Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
Published date:
11/03/2022
Excerpt:
Patients (Pts) with relapsed or refractory (RR) MCL with ≥1 prior line of therapy (LOT) or treatment-naïve (TN) or RR CLL with ≥1 prior LOT were enrolled....For CLL pts with p53 alterations, overall efficacy with Zilo+Ibr is also very promising with LPFS at 30 mos of 100%...
DOI:
https://doi.org/10.1182/blood-2022-167153
